Floatz Rating
B62/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04310397CT.gov Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma | — | Terminated | — | — | — |
NCT03972046CT.gov Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma | — | Withdrawn | — | — | — |
NCT02910700CT.gov Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma | — | Active Not Recruiting | — | — | — |
NCT02231775CT.gov Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation | — | Active Not Recruiting | — | — | — |
NCT02097225CT.gov Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | — | Terminated | — | — | — |
NCT01989585CT.gov Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma | — | Active Not Recruiting | — | — | — |
NCT01940809CT.gov Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cutaneous Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Trametinib (this asset) | M.D. Anderson Cancer Center | P2 | B · 62 |
| Alpha-Interferon | MIPO Clinic | P3 | BBB |
| TIL | City of Hope Medical Center | P2 | BBB |
| Cis-Diamminedichloroplatinum Ii | MIPO Clinic | P3 | BBB |
| Dacarbazine | Linnaeus Therapeutics, Inc. | P3 | BBB |
| Tyrosinase Peptide | University of Southern California | P3 | BBB |
| Nivestim | Vastra Gotaland Region | P3 | BB |
| Multi-Epitope Melanoma Peptide Vaccine | Craig L Slingluff, Jr | P2 | BB |
| Mart-1 Antigen | Mayo Clinic | P2 | BB |
+42 more in the Cutaneous Melanoma cohort
Other indications for Trametinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Melanoma | — | P4 | BB · 69 |
| Anaplastic Pleomorphic Xanthoastrocytoma | — | P4 | BB · 69 |
| Anaplastic Oligodendroglioma | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Trametinib in Cutaneous Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/trametinib-cutaneous-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →